Company news
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news
Tonix Pharmaceuticals Holding Corp. news releases on 6ix. Latest, Jun 29, 2020: Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102…
Press releases — page 8
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule
June 28, 2020
Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020
June 21, 2020
Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration
June 17, 2020
Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020
June 16, 2020
Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License
June 10, 2020
Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors
June 9, 2020
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
May 31, 2020
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
May 18, 2020
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
May 11, 2020
Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
May 6, 2020
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
April 23, 2020
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
March 23, 2020
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering
March 2, 2020
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market
February 27, 2020
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
February 25, 2020
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering
February 10, 2020
Tonix Pharmaceuticals Prices $7.5 million Public Offering
February 6, 2020
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
February 4, 2020
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
January 23, 2020
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study
December 15, 2019
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
December 10, 2019
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
December 9, 2019
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
December 2, 2019
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
November 25, 2019
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
November 20, 2019
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder
November 19, 2019
Tonix Pharmaceuticals Prices $9.0 Million Public Offering
November 14, 2019
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
November 7, 2019
Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting
November 3, 2019
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
October 30, 2019
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
October 22, 2019
Tonix Pharmaceuticals Joins the Alliance for Biosecurity
October 14, 2019
Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD
October 6, 2019
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg
October 2, 2019
Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers
September 15, 2019
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
April 3, 2019